Investors

Investment opportunity

  • Very attractive area of immuno-oncology with renewed interest for innovative therapeutic vaccines approaches as illustrated by recent deals (several billion USD since 2013) and Series A rounds. 
  • A robust preclinical PoC, a First-in-human in melanoma and a candidate for lung cancer (potentially relevant for other cancer types) 
  • Disruptive and versatile technology platform with broad IP and rapid generation of clinical candidates in any cancer type and various tumor antigen types. 
  • Spin-off from the EFS (French Blood Bank) with access to its R&D and GMP infrastructures. 
  • Strong team with complementary academic and industrial track record.